UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000059111 |
|---|---|
| Receipt number | R000067574 |
| Scientific Title | A study to measure the GI: an open-label study |
| Date of disclosure of the study information | 2025/09/17 |
| Last modified on | 2025/09/17 14:10:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study to measure the glycemic index (GI)
Acronym
A study to measure the GI
Scientific Title
A study to measure the GI: an open-label study
Scientific Title:Acronym
A study to measure the GI
Region
| Japan |
Condition
Condition
Healthy Japanese
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effect of consuming the test food on the GI.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. The GI of the test food
Key secondary outcomes
1. Blood glucose levels at 15, 30, 45, 60, 90, and 120 minutes after intervention, and the maximum blood concentration (Cmax)
2. Incremental area under the curve (IAUC) of total cholesterol and triglyceride
3. Total cholesterol and triglyceride levels at 30, 60, and 120 minutes after intervention and their Cmax
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Educational,Counseling,Training
Type of intervention
| Food |
Interventions/Control_1
<Duration>
Single ingestion
<Test product>
Test food: Comeat(R) (fermented rice product, 128.9 g)
<Carbohydrate load>
Sato No Gohan (150 g)
<Administration>
Test food: Add 100 mL of hot water to the test food, wait 5 minutes, and consume within 10 minutes. If consuming within 10 minutes is difficult, consume within 15 minutes.
Carbohydrate load: Consume within 10 minutes. If consuming within 10 minutes is difficult, consume within 15 minutes. Approximately 150 cc of hot water or water may be taken with it.
*The intervention sequence is: Carbohydrate load, followed by Carbohydrate load, followed by Test food.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 50 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Individuals aged 20 or more and less than 50
4. Healthy individuals
5. Individuals whose body mass index (BMI) is less than 30 kg/m2
Key exclusion criteria
1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
5. Individuals who have food allergies and/or food intolerances. Particularly, individuals who have lactose intolerance.
6. Individuals who have abnormal glucose tolerance
7. Individuals who take medications known to affect glucose tolerance
8. Individuals who have used insulin for diabetes or taken antihyperglycemic drugs
9. Individuals who have been hospitalized for treatment or surgery within the last three months
10. Individuals who plan to have surgery within two weeks after this study
11. Individuals who have or are undergoing medical treatment for diseases which influence digestion and absorption of nutrients
12. Individuals who are taking steroids, protease inhibitors, or antipsychotics
13. Individuals who are taking or using medicines (including herbal medicines) or supplements
14. Individuals who are allergic to medicines or foods related to the test product
15. Individuals who are pregnant, lactating, or planning to become pregnant during this study
16. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
17. Individuals who are judged as ineligible to participate in this study by the physician
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Organization
Medical Corporation Seishinkai, Takara Clinic
Division name
Director
Zip code
141-0022
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL
03-5793-3623
t-takara@takara-clinic.com
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
Agro Ludens Inc.
Institute
Department
Personal name
Funding Source
Organization
Agro Ludens Inc.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 09 | Month | 17 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2025 | Year | 08 | Month | 06 | Day |
Date of IRB
| 2025 | Year | 08 | Month | 06 | Day |
Anticipated trial start date
| 2025 | Year | 09 | Month | 17 | Day |
Last follow-up date
| 2025 | Year | 11 | Month | 12 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2025 | Year | 09 | Month | 17 | Day |
Last modified on
| 2025 | Year | 09 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067574
